20VC: Inside Carnegie Mellon's $4BN Endowment | Why 90% of LPs Shouldn't Invest in VC | The $140BN Problem with Multi-Stage Funds | The Hidden Math Behind DPI, TVPI, and Illiquidity with Miles Dieffenbach
20VC: Inside Carnegie Mellon's $4BN Endowment | Why 90% of LPs Shouldn't Invest in VC | The $140BN Problem with Multi-Stage Funds | The Hidden Math Behind DPI, TVPI, and Illiquidity with Miles Dieffenbach
20VC: Inside Carnegie Mellon's $4BN Endowment | Why 90% of LPs Shouldn't Invest in VC | The $140BN Problem with Multi-Stage Funds | The Hidden Math Behind DPI, TVPI, and Illiquidity with Miles Dieffenbach
In this insightful conversation, Miles Dieffenbach, Managing Director of Investments at Carnegie Mellon University, shares his personal journey through cancer and how it shaped his resilient mindset. Transitioning into his professional expertise, he provides a deep dive into managing a $4 billion endowment, shedding light on the complexities of venture capital, private equity, and alternative investments. The discussion also explores broader themes in the venture capital ecosystem, including performance challenges, access issues, and evolving market dynamics.
Miles Dieffenbach discusses the underperformance of venture capital relative to its risk profile, noting that many limited partners (LPs) are poorly positioned due to access issues and misaligned incentives. He highlights the challenges of seed funds, the dominance of top-tier multi-stage firms like Index, and the growing concerns around inflated valuations in AI startups such as OpenAI. Dieffenbach critiques the venture capital model, emphasizing the importance of track record, founder relationships, and disciplined fundraising. He also touches on the difficulties of achieving high returns in today’s environment, the risks of founder-friendly terms, and the need for a margin of safety in valuations. Throughout, he offers a candid view of the venture capital landscape, blending institutional investing strategy with personal insight.
05:45
05:45
Decided to face cancer actively after diagnosis, leading to recovery in four months
07:02
07:02
Private equity has been self-funding for three years and is the main distribution contributor
10:46
10:46
Venture capital is considered the riskiest private asset class.
13:31
13:31
New allocators are unlikely to access top-decile managers.
16:01
16:01
Union Square is noted for its strength in selling within venture capital.
22:29
22:29
Premier funds have strong networks while esoteric strategies target niche markets
24:02
24:02
Sourcing in venture capital is a young person's game and involves a lot of luck and hustle.
31:52
31:52
GPs should aim for a diversified LP base with no single investor exceeding 10% concentration
34:31
34:31
Selling part of the management company is a red flag in fundraising
40:51
40:51
Index praised for performance-driven culture and restraint in fund-raising.
58:32
58:32
A 13-year fund benefited significantly from Circle's growth into a $50B company after being undervalued.
